Stability, blood partition, and protein binding of a chemoprotective agent, 2-(allylthio)pyrazine

Research Communications in Molecular Pathology and Pharmacology

Volumn 101, Issue 2, 1998, Pages 171-178

  Han, Kye S ^a   Woo, Seong Ju ^b   Koo, Chang Hui ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Bukwang Pharmaceutical Company   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ALLYLTHIO)PYRAZINE; BUFFER; CHLORIDE ION; HEPARIN; HUMAN SERUM ALBUMIN; OROSOMUCOID; PROTECTIVE AGENT; UNCLASSIFIED DRUG;

ARTICLE; BLOOD; DRUG PROTEIN BINDING; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RABBIT; STOMACH JUICE;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; ENZYME INHIBITORS; GASTRIC JUICE; HUMANS; HYDROGEN-ION CONCENTRATION; PYRAZINES; RABBITS; SERUM ALBUMIN;

EID: 0031784271     PISSN: 10780297     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Han, K. S., Woo, S.-J., Koo, C. H., and Lee, M. G. (in press) Determination of a chemoprotective agent, 2-(allylthio)pyrazine, in plasma, urine and tissue homogenates by high-performance liquid chromatography. J. Chromatogr. B.
2. X-174 DNA strand breakage. Yakhak Hoeji. 40: 727-733.
3. Kim, S. H., Han, K. S., Choi, W. S., Kang, M. S., and Lee, M. G. (1997) Stability, blood partition, and pharmacokinetics of a new reversible proton pump inhibitor, YJA-20379-1. Res. Commun. Mol. Pathol. Pharmacol. 98: 77-84.
4. Kim, N. D., Kwak, M. K., and Kim, S. G. (1997) Inhibition of cytochrome P450 2E1 expression by 2-(allylthio)pyrazine, a potential chemoprotective agent: Hepatoprotective effects. Biochem. Pharmacol. 53: 261-269.
5. Kwak, M. K., Lee, W. I., Kim, N. D., and Lee, M. G. (1998) Metabolic changes of acetaminophen after intravenous administration to rats pretreated with 2-(allylthio)pyrazine. Biopharm. Drug Dispos. 19: 273-277.
6. Lee, S. H. and Lee, M. G. (1995a) Stability, tissue metabolism, tissue distribution and blood partition of azosemide. Biopharm. Drug Dispos. 16: 547-561.
7. Lee, S. H. and Lee, M. G. (1995b) Factors influencing the protein binding of azosemide using an equilibrium dialysis technique. Biopharm. Drug Dispos. 16: 615-626.
8. Lee, W. I., Yoon, W. H., Park, J. H., Lee, J. W., Shim, C.-K., and Lee, M. G. (1995) Factors influencing the protein binding of YH-439 using an equilibrium dialysis technique. A new hepatoprotective agent. Biopharm. Drug Dispos. 16: 775-789.
9. Lin, J. H. (1994) Dose-dependent pharmacokinetics: Experimental observations and theoretical considerations. Biopharm. Drug Dispos. 15: 1-31.
10. Nam, S. Y. (1998) Molecular pharmacological studies on the radioactive mechanisms and the effects of radioprotective agents: The role of epoxide hydrolase and glutathione S-transferase expression. Ph. D. Thesis, Duksung Women's University. Seoul, South Korea.
11. Shin, W. G., Lee, M. G., Lee, M. H., and Kim, N. D. (1991) Factors influencing the protein binding of vancomycin. Biopharm. Drug Dispos. 12: 637-646.
12. Surh, Y-J., Park, K. K., Kim, S. G., Sohn, Y., Kim, N. D., Liem, A., and Miller, J. A. (1997) Chemoprevention of vinyl carbamate- or vinyl carbamate epoxide-induced hepatotoxicity, mutagenicity, and tumorigenicity by 2-(allylthio)pyrazine. Proc. Am. Assoc. Cancer Res. 38: 370.